<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="under evaluation as potential treatments in the fight against coronavirus" exact="disease" post="2019 (COVID-19). Plasma from patients that have overcome COVID-19"/>
 <result pre="convalescent plasma, is a treatment option with considerable background in" exact="viral" post="diseases such as Spanish influenza, H1N1, Ebola, Severe Acute"/>
 <result pre="background in viral diseases such as Spanish influenza, H1N1, Ebola," exact="Severe" post="Acute Respiratory Syndrome (SARS), and Middle East Respiratory Syndrome"/>
 <result pre="in viral diseases such as Spanish influenza, H1N1, Ebola, Severe" exact="Acute" post="Respiratory Syndrome (SARS), and Middle East Respiratory Syndrome (MERS)."/>
 <result pre="viral diseases such as Spanish influenza, H1N1, Ebola, Severe Acute" exact="Respiratory" post="Syndrome (SARS), and Middle East Respiratory Syndrome (MERS). Although"/>
 <result pre="diseases such as Spanish influenza, H1N1, Ebola, Severe Acute Respiratory" exact="Syndrome" post="(SARS), and Middle East Respiratory Syndrome (MERS). Although convalescent"/>
 <result pre="H1N1, Ebola, Severe Acute Respiratory Syndrome (SARS), and Middle East" exact="Respiratory" post="Syndrome (MERS). Although convalescent plasma has historically proven beneficial"/>
 <result pre="Ebola, Severe Acute Respiratory Syndrome (SARS), and Middle East Respiratory" exact="Syndrome" post="(MERS). Although convalescent plasma has historically proven beneficial in"/>
 <result pre="plasma has historically proven beneficial in the treatment of some" exact="viral" post="diseases, its use is still explorative in the context"/>
 <result pre="be a safe option, but potential risks such as transfusion-related" exact="acute" post="lung injury and antibody-dependent enhancement are discussed. Authorities including"/>
 <result pre="(FDA), and scientific associations such as the International Society of" exact="Blood" post="Transfusion (ISBT) and the European Blood Alliance (EBA), have"/>
 <result pre="the International Society of Blood Transfusion (ISBT) and the European" exact="Blood" post="Alliance (EBA), have provided guidance into the selection criteria"/>
 <result pre="of significant deterioration can prove valuable in this direction. Introduction" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia was first"/>
 <result pre="significant deterioration can prove valuable in this direction. Introduction Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia was first noted"/>
 <result pre="deterioration can prove valuable in this direction. Introduction Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) pneumonia was first noted in"/>
 <result pre="can prove valuable in this direction. Introduction Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) pneumonia was first noted in Wuhan"/>
 <result pre="this direction. Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="pneumonia" post="was first noted in Wuhan (China) in December 20191"/>
 <result pre="first noted in Wuhan (China) in December 20191 and the" exact="disease" post="induced by the virus has been termed coronavirus infectious"/>
 <result pre="the disease induced by the virus has been termed coronavirus" exact="infectious disease" post="2019 (COVID-19). To date, various treatment regimens are being"/>
 <result pre="disease induced by the virus has been termed coronavirus infectious" exact="disease" post="2019 (COVID-19). To date, various treatment regimens are being"/>
 <result pre="In recent history, convalescent plasma has been successfully used in" exact="viral" post="outbreaks and epidemics. In as early as the 1918â€&quot;1925"/>
 <result pre="Spanish influenza pandemic, studies evaluated convalescent blood products to treat" exact="pneumonia" post="due to Spanish influenza in hospitals, presenting assessment versus"/>
 <result pre="the treatment early, namely within the first four days of" exact="pneumonia" post="complications.9 Although these early epidemiological studies had been rather"/>
 <result pre="later, in the context of pandemic influenza A (H1N1) 2009" exact="virus infection," post="convalescent plasma treatment was able to significantly reduce respiratory"/>
 <result pre="virus infection, convalescent plasma treatment was able to significantly reduce" exact="respiratory" post="tract viral load, serum cytokine response (interleukin-6, interleukin-19, tumor"/>
 <result pre="convalescent plasma treatment was able to significantly reduce respiratory tract" exact="viral" post="load, serum cytokine response (interleukin-6, interleukin-19, tumor necrosis factor-alpha),"/>
 <result pre="reduce respiratory tract viral load, serum cytokine response (interleukin-6, interleukin-19," exact="tumor" post="necrosis factor-alpha), and mortality in a comparative study recruiting"/>
 <result pre="subsequent systematic review and meta-analysis synthesized 32 studies of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus infection and severe influenza and"/>
 <result pre="systematic review and meta-analysis synthesized 32 studies of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus infection and severe influenza and highlighted"/>
 <result pre="review and meta-analysis synthesized 32 studies of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus infection and severe influenza and highlighted the"/>
 <result pre="synthesized 32 studies of severe acute respiratory syndrome (SARS) coronavirus" exact="infection" post="and severe influenza and highlighted the consistent evidence for"/>
 <result pre="the odds of death.14 In the case of Middle East" exact="Respiratory" post="Syndrome (MERS), a protocol of convalescent plasma therapy for"/>
 <result pre="odds of death.14 In the case of Middle East Respiratory" exact="Syndrome" post="(MERS), a protocol of convalescent plasma therapy for patients"/>
 <result pre="a protocol of convalescent plasma therapy for patients with the" exact="disease" post="was established in 2015. According to this protocol, subjects"/>
 <result pre="clinical studies was conducted during the West Africa Ebola virus" exact="disease" post="outbreak, gathering a pool of 1147 individuals. This analysis"/>
 <result pre="of 1147 individuals. This analysis acknowledged that studies were considerably" exact="limited" post="by the lack of randomization.17 A large, non-randomized study"/>
 <result pre="indices. Notably, convalescent plasma was administered relatively late during the" exact="disease" post="in all patients, namely between days 19 and 22"/>
 <result pre="their series of four COVID-19 patients in Guangdong (China), with" exact="total" post="volumes administered ranging between 200 and 2400â€ŠmL. All patients"/>
 <result pre="them, those who received the transfusion relatively early during the" exact="disease" post="(days 10 and 11 from initiation of symptoms) showed"/>
 <result pre="scenarios, including persistent SARS-CoV-2 detection, consolidation or extensive lesions in" exact="chest" post="CT, comorbidity with SjÃ¶gren syndrome and post-discharge positivity to"/>
 <result pre="consolidation or extensive lesions in chest CT, comorbidity with SjÃ¶gren" exact="syndrome" post="and post-discharge positivity to SARS-CoV-2; improvement and promising results"/>
 <result pre="the new treatment; administration of convalescent plasma in critical, end-stage" exact="respiratory" post="failure, at a late stage during the course of"/>
 <result pre="failure, at a late stage during the course of the" exact="disease" post="(median: 21.5 days after first detection) was associated with"/>
 <result pre="21.5 days after first detection) was associated with suppression of" exact="viral" post="shedding but ultimately death in 5 out of 6"/>
 <result pre="is in line with observations in other diseases, such as" exact="pneumococcal pneumonia," post="where no benefit is noted if the antibody is"/>
 <result pre="indicate that patients receiving transfusions earlier than 14 days post" exact="infection" post="may benefit from convalescent plasma treatment. Mechanism of actions"/>
 <result pre="actions Convalescent plasma may offer various beneficial actions in COVID-19" exact="disease" post="(Fig. 1). First and foremost, the apparent mechanism pertains"/>
 <result pre="administration of convalescent plasma at the early stage of the" exact="disease" post="would be more effective.30 Viremia peak is noted in"/>
 <result pre="effective.30 Viremia peak is noted in the first week of" exact="infection" post="in the majority of viral illnesses and a primary"/>
 <result pre="in the first week of infection in the majority of" exact="viral" post="illnesses and a primary immune response of the host"/>
 <result pre="of infection in the majority of viral illnesses and a" exact="primary" post="immune response of the host is usually developed by"/>
 <result pre="in process, a detailed analysis of 9 cases with mild" exact="upper" post="respiratory tract symptoms revealed that seroconversion occurred 6 to"/>
 <result pre="process, a detailed analysis of 9 cases with mild upper" exact="respiratory" post="tract symptoms revealed that seroconversion occurred 6 to 12"/>
 <result pre="Seroconversion coincided with a slow but steady decline of sputum" exact="viral" post="load.35 In another study, the majority of PCR-confirmed SARS-CoV-2-infected"/>
 <result pre="majority of PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after" exact="disease" post="onset.36 A study on 173 COVID-19 patients showed that"/>
 <result pre="IgG since day 15 after onset, and higher titer of" exact="total" post="antibodies correlated with worsened clinical classification.37 To further assess"/>
 <result pre="further assess the time for seroconversion and its correlation with" exact="disease" post="severity and antibody titers, additional longitudinal studies evaluating large"/>
 <result pre="symptoms are needed. Registered trials on convalescent plasma in COVID-19" exact="disease" post="Tracing the progression of research on the potential utilization"/>
 <result pre="the Netherlands. If completed, these studies would examine a minimum" exact="total" post="of 1106 patients. At present, 5 studies are either"/>
 <result pre="days from the beginning of illness (NCT04333251) or, less strictly," exact="acute" post="respiratory distress syndrome (ARDS) lasting less than 10 days"/>
 <result pre="from the beginning of illness (NCT04333251) or, less strictly, acute" exact="respiratory" post="distress syndrome (ARDS) lasting less than 10 days (NCT04321421)."/>
 <result pre="beginning of illness (NCT04333251) or, less strictly, acute respiratory distress" exact="syndrome" post="(ARDS) lasting less than 10 days (NCT04321421). Variable degrees"/>
 <result pre="(NCT04327349) or critical illness (NCT04332380) was an exclusion criterion. The" exact="total" post="amount of convalescent plasma ranges from 1 to 3"/>
 <result pre="will be recruited, including elderly subjects and patients suffering from" exact="chronic" post="conditions. This strategy of prophylaxis has been successfully implemented"/>
 <result pre="prophylaxis has been successfully implemented in the prevention of other" exact="viral" post="diseases via passive immunity, such as the case of"/>
 <result pre="via passive immunity, such as the case of administration of" exact="hepatitis" post="B immune globulin, human rabies immune globulin, and polyclonal"/>
 <result pre="the case of administration of hepatitis B immune globulin, human" exact="rabies" post="immune globulin, and polyclonal hyperimmune globulin for respiratory syncytial"/>
 <result pre="globulin, human rabies immune globulin, and polyclonal hyperimmune globulin for" exact="respiratory" post="syncytial virus (RSV), or more recently palivizumab, a humanized"/>
 <result pre="2 studies were identified (Table 2Â Â Â Â ," exact="lower" post="panels). The first one (NCT04261426) focuses on early administration"/>
 <result pre="the aim to evaluate this experimental treatment in severe COVID-19" exact="pneumonia" post="cases in China. The examination of studies registered in"/>
 <result pre="was a single-arm trial. If all studies are complete, a" exact="total" post="of 680 patients will have been evaluated. All studies"/>
 <result pre="among the exclusion criteria, pregnancy, lactation, immunoglobulin allergy/allergy to plasma," exact="immunoglobulin A deficiency," post="and other contraindications for plasma transfusion (such as heart"/>
 <result pre="A deficiency, and other contraindications for plasma transfusion (such as" exact="heart" post="failure) have been often stated. Interestingly, some studies (ChiCTR2000029757,"/>
 <result pre="Interestingly, some studies (ChiCTR2000029757, ChiCTR2000030010, ChiCTR2000030702, ChiCTR2000030929) provide shock and" exact="disseminated intravascular coagulation" post="as an exclusion criterion. No details have been provided"/>
 <result pre="2020). Cancelled Studies have not been Included. Current situation â€&quot;" exact="American" post="and European framework for donors On March 24, 2020,"/>
 <result pre="necessitated. Male donors are eligible; special attention is paid to" exact="female" post="donors who should be negative for human leukocyte antigen"/>
 <result pre="human leukocyte antigen (HLA) antibodies in case of previous pregnancy." exact="General" post="donor eligibility requirements along with the additional criteria for"/>
 <result pre="the additional criteria for plasmapheresis should be also met, including" exact="infection" post="status control. The FDA has also provided guidance on"/>
 <result pre="standards, labeling, and recordkeeping.40 Regarding donors, the International Society of" exact="Blood" post="Transfusion (ISBT) Working Party set an interval of 14"/>
 <result pre="recovery and necessitated a non-reactivity of the sample for human" exact="immunodeficiency" post="virus (HIV), hepatitis B virus (HBV), hepatitis C virus"/>
 <result pre="a non-reactivity of the sample for human immunodeficiency virus (HIV)," exact="hepatitis" post="B virus (HBV), hepatitis C virus (HCV), syphilis, and"/>
 <result pre="sample for human immunodeficiency virus (HIV), hepatitis B virus (HBV)," exact="hepatitis C" post="virus (HCV), syphilis, and locally transmitted infections. As a"/>
 <result pre="infections. As a means to avoid the incidence of transfusion-related" exact="acute" post="lung injury (TRALI)â€&quot;a serious condition emerging within 6â€Šhours from"/>
 <result pre="a level greater than 1:320, although it was recognized that" exact="lower" post="thresholds could also be effective.42 Convalescent plasma recipients and"/>
 <result pre="of convalescent plasma should be COVID-19 positive patients with severe" exact="disease" post="(dyspnea, respiratory frequency â‰¥ 30/min, blood oxygen saturation 93%"/>
 <result pre="plasma should be COVID-19 positive patients with severe disease (dyspnea," exact="respiratory" post="frequency â‰¥ 30/min, blood oxygen saturation 93% or less,"/>
 <result pre="respiratory frequency â‰¥ 30/min, blood oxygen saturation 93% or less," exact="partial" post="pressure of arterial oxygen to fraction of inspired oxygen"/>
 <result pre="infiltrates &amp;gt; 50% within 24 to 48â€Šhours) or a life-threatening" exact="disease" post="(respiratory failure, septic shock, multiple organ dysfunction) who have"/>
 <result pre="within 24 to 48â€Šhours) or a life-threatening disease (respiratory failure," exact="septic shock," post="multiple organ dysfunction) who have given informed consent for"/>
 <result pre="to convalescent plasma administration by April 27, 2020, enrolled a" exact="total" post="of 5,968 patients, with 2576 receiving convalescent plasma.43 Convalescent"/>
 <result pre="enhancement (ADE) of coronavirus entry. This has been reported in" exact="viral" post="diseases and refers to an enhancement of disease in"/>
 <result pre="reported in viral diseases and refers to an enhancement of" exact="disease" post="in the presence of certain antibodies.44 Keeping in mind"/>
 <result pre="major problem; however, surveillance is warranted.29 In accordance to the" exact="Infectious" post="Diseases Society of America Guidelines on the treatment and"/>
 <result pre="problem; however, surveillance is warranted.29 In accordance to the Infectious" exact="Diseases" post="Society of America Guidelines on the treatment and management"/>
 <result pre="framework of a clinical trial.45 Similarly, the International Society of" exact="Blood" post="Transfusion (ISBT) Working Party on Global Blood Safety has"/>
 <result pre="International Society of Blood Transfusion (ISBT) Working Party on Global" exact="Blood" post="Safety has underlined that the clinical use of convalescent"/>
 <result pre="as well as transfusion.32 Facing the COVID-19 pandemic, the European" exact="Blood" post="Alliance (EBA), together with the European Commission's Directorate-General for"/>
 <result pre="to collect, monitor, and share all information on convalescent plasma.46" exact="Blood" post="establishments will organize collection, enter donor data in the"/>
 <result pre="References References 1.WuZMcGooganJMCharacteristics of and Important Lessons From the Coronavirus" exact="Disease" post="2019 (COVID-19) Outbreak in China: Summary of a Report"/>
 <result pre="a Report of 72314 Cases From the Chinese Center for" exact="Disease" post="Control and Prevention. JAMA.2020;[Epub ahead of print]. 2.CunninghamACGohHPKohDTreatment of"/>
 <result pre="old tricks for new challenges. Crit Care.2020;24:91.32178711 3.CaoYCDengQXDaiSXRemdesivir for severe" exact="acute" post="respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of"/>
 <result pre="tricks for new challenges. Crit Care.2020;24:91.32178711 3.CaoYCDengQXDaiSXRemdesivir for severe acute" exact="respiratory" post="syndrome coronavirus 2 causing COVID-19: an evaluation of the"/>
 <result pre="for new challenges. Crit Care.2020;24:91.32178711 3.CaoYCDengQXDaiSXRemdesivir for severe acute respiratory" exact="syndrome" post="coronavirus 2 causing COVID-19: an evaluation of the evidence."/>
 <result pre="et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related" exact="respiratory" post="failure: a case report. Ann Oncol. 2020 April 2."/>
 <result pre="print] 7.ZhangXSongKTongFet al.First case of COVID-19 in a patient with" exact="multiple myeloma" post="successfully treated with tocilizumab. Blood Adv.2020;4:1307â€&quot;1310.32243501 8.Zhang C, Wu"/>
 <result pre="7.ZhangXSongKTongFet al.First case of COVID-19 in a patient with multiple" exact="myeloma" post="successfully treated with tocilizumab. Blood Adv.2020;4:1307â€&quot;1310.32243501 8.Zhang C, Wu"/>
 <result pre="in a patient with multiple myeloma successfully treated with tocilizumab." exact="Blood" post="Adv.2020;4:1307â€&quot;1310.32243501 8.Zhang C, Wu Z, Li JW, et al."/>
 <result pre="C, Wu Z, Li JW, et al. The cytokine release" exact="syndrome" post="(CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist"/>
 <result pre="a future H5N1 treatment?Ann Intern Med.2006;145:599â€&quot;609.16940336 10.ParkWHFreemanRGThe prophylactic use of" exact="measles" post="convalescent serum. JAMA.1926;87:556â€&quot;558. 11.ParkWHTherapeutic use of antipoliomyelitis serum in"/>
 <result pre="mortality in patients with severe pandemic influenza A (H1N1) 2009" exact="virus infection." post="Clin Infect Dis.2011;52:447â€&quot;456.21248066 14.Mair-JenkinsJSaavedra-CamposMBaillieJKet al.The effectiveness of convalescent plasma"/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysis."/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysis. J Infect"/>
 <result pre="effects of convalescent plasma therapy for patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a study protocol. Springerplus.2015;4:709.26618098 16.KoJHSeokHChoSYet al.Challenges"/>
 <result pre="of convalescent plasma therapy for patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a study protocol. Springerplus.2015;4:709.26618098 16.KoJHSeokHChoSYet al.Challenges of"/>
 <result pre="16.KoJHSeokHChoSYet al.Challenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="coronavirus infection: a single centre experience. Antivir Ther.2018;23:617â€&quot;622.29923831 17.DoddLEFollmannDProschanMet"/>
 <result pre="of clinical studies conducted during the West Africa Ebola virus" exact="disease" post="outbreak confirms the need for randomized control groups. Sci"/>
 <result pre="18.van GriensvenJEdwardsTde LamballerieXet al.Evaluation of convalescent plasma for ebola virus" exact="disease" post="in Guinea. N Engl J Med.2016;374:33â€&quot;42.26735992 19.World Health Organization."/>
 <result pre="al.Use of convalescent plasma therapy in two COVID-19 patients with" exact="acute" post="respiratory distress syndrome in Korea. J Korean Med Sci.2020;35:e149.32281317"/>
 <result pre="of convalescent plasma therapy in two COVID-19 patients with acute" exact="respiratory" post="distress syndrome in Korea. J Korean Med Sci.2020;35:e149.32281317 26.Zeng"/>
 <result pre="plasma therapy in two COVID-19 patients with acute respiratory distress" exact="syndrome" post="in Korea. J Korean Med Sci.2020;35:e149.32281317 26.Zeng QL, Yu"/>
 <result pre="Gou JJ, et al. Effect of convalescent plasma therapy on" exact="viral" post="shedding and survival in COVID-19 patients. J Infect Dis."/>
 <result pre="[Epub ahead of print]. 28.CasadevallAScharffMDSerum therapy revisited: animal models of" exact="infection" post="and development of passive antibody therapy. Antimicrob Agents Chemother.1994;38:1695â€&quot;1702.7985997"/>
 <result pre="Clinical presentation and virological assessment of hospitalized cases of coronavirus" exact="disease" post="2019 in a travel-associated transmission cluster. 2020; 10.1101/2020.03.05.20030502. Accessed"/>
 <result pre="12, 2020. 36.Okba NMA, Muller MA, Li W, et al." exact="Severe" post="acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus"/>
 <result pre="2020. 36.Okba NMA, Muller MA, Li W, et al. Severe" exact="acute" post="respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease"/>
 <result pre="36.Okba NMA, Muller MA, Li W, et al. Severe acute" exact="respiratory" post="syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019"/>
 <result pre="NMA, Muller MA, Li W, et al. Severe acute respiratory" exact="syndrome" post="coronavirus 2-specific antibody responses in coronavirus disease 2019 patients."/>
 <result pre="Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus" exact="disease" post="2019 patients. Emerg Infect Dis. 2020 April 8. [Epub"/>
 <result pre="of print]. 37.Zhao J, Yuan Q, Wang H, et al." exact="Antibody" post="responses to SARS-CoV-2 in patients of novel coronavirus disease"/>
 <result pre="al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus" exact="disease" post="2019. Clin Infect Dis. 2020 March 28. [Epub ahead"/>
 <result pre="J Virol.2020;94:e02015â€&quot;e02019.31826992 45.Bhimraj A, Morgan RL, Shumaker AH, et al." exact="Infectious" post="Diseases Society of America Guidelines on the Treatment and"/>
 <result pre="Virol.2020;94:e02015â€&quot;e02019.31826992 45.Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious" exact="Diseases" post="Society of America Guidelines on the Treatment and Management"/>
 <result pre="with COVID-19 Infection. 2020; https://www.idsociety.org/practiceguideline/covid-19-guideline-treatment-and-management/. Accessed April 12, 2020. 46.European" exact="Blood" post="Alliance. COVID-19 and blood establishments. Update April 08, 2020."/>
</results>
